Developing novel new therapies for retinal disease
CavtheRx is a pre-clinical stage biopharmaceutical company focused on developing innovative caveolin modulators which have been shown to regulate signal transduction pathways. The unique mechanisms of action that provide anti-angiogenic and anti-inflammatory effects which block vascular leakage and edema suggest that caveolin modulators may have a role in addressing a wide range of chronic disease states.
Our initial development plans focus on the treatment of sight-threatening neovascular eye diseases which include neovascular age-related macular degeneration (wet AMD), the leading cause of blindness in the Western world, and diabetic retinopathy. Despite the advances in treatment provided by anti-VEGF agents, studies have reported up to 40% of patients achieve sub-optimal BCVA results. In vitro and in vivo models demonstrate inhibition of CNV with Cavtratin alone and a synergestic effect with anti-VEGF therapy.